Results 61 to 70 of about 1,936 (110)

Kinetoplastida: new therapeutic strategies

Parasite, 2008
New formulations and therapeutic switching of the established drugs, amphotericin B and paromomycin, together with the discovery of miltefosine, have significantly improved the opportunities for treatment of visceral leishmaniasis (VL) chemotherapy ...
Croft S.L.
doaj   +1 more source

Targeting Pharmacological and Nanotechnology Based Therapeutics for Management of Hirsutism: A Comprehensive State-of-the-Art [PDF]

Pharmaceutical Sciences
Hirsutism is characterized by the excessive growth of coarse hair in women, resembling the typical pattern seen in men. It affects between 5 to 10 % of females of reproductive age.
Ishrat Zahoor, Sukhbir Singh, Neelam Sharma, Ikmeet Kaur Grewal, Shahid Nazir Wani   +4 more
doaj   +1 more source

Endocrine disorders in adult patients with inherited metabolic diseases: Their diagnosis and long‐term management

Clinical Endocrinology, Volume 101, Issue 5, Page 562-568, November 2024.
Adrian H. Heald, John Bassett, Nuria Puente‐Ruiz, Peter Clayton, Karolina M. Stepien   +4 more
wiley   +1 more source

Insights into antitrypanosomal drug mode-of-action from cytology-based profiling.

PLoS Neglected Tropical Diseases, 2018
Chemotherapy continues to have a major impact on reducing the burden of disease caused by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal drugs typically remains unclear or only partially characterised.
James A Thomas, Nicola Baker, Sebastian Hutchinson, Caia Dominicus, Anna Trenaman, Lucy Glover, Sam Alsford, David Horn   +7 more
doaj   +1 more source

The detection and treatment of human African trypanosomiasis

Research and Reports in Tropical Medicine, 2012
Bernard Bouteille,1 Alain Buguet21Laboratory of Parasitology, Dupuytren University Hospital of Limoges, France; 2Polyclinic Marie-Louise Poto-Djembo, Pointe-Noire, CongoAbstract: Human African trypanosomiasis (HAT) is caused by the injection of ...
Bouteille B, Buguet A
doaj  

Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis

Research and Reports in Tropical Medicine, 2012
Jose R Franco,1 Pere P Simarro,1 Abdoulaye Diarra,2 Jose A Ruiz-Postigo,3 Mireille Samo,1 Jean G Jannin11World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland; 2World Health ...
Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Samo M, Jannin JG   +5 more
doaj  

Polyamine Metabolism for Drug Intervention in Trypanosomatids

Pathogens
Neglected tropical diseases transmitted by trypanosomatids include three major human scourges that globally affect the world’s poorest people: African trypanosomiasis or sleeping sickness, American trypanosomiasis or Chagas disease and different types of
Yolanda Pérez-Pertejo, Carlos García-Estrada, María Martínez-Valladares, Sankaranarayanan Murugesan, Rosa M. Reguera, Rafael Balaña-Fouce   +5 more
doaj   +1 more source

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-blinded, Randomized Clinical Trial. [PDF]

Cancer Prev Res (Phila)
Morgan DR, Dominguez RL, Norwood DA, Montalvan-Sanchez EE, Piazuelo MB, Rodriguez-Murillo A, Delgado AG, Hernandez-Marrero J, Gonzalez-Pons M, Beasley TM, Cruz-Correa M, Wilson KT.   +11 more
europepmc   +1 more source

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. [PDF]

J Clin Oncol
Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin VA.   +28 more
europepmc   +1 more source

Targeted Therapies in Neuroblastoma: A History and a View to the Future. [PDF]

Cancers (Basel)
Shah N.
europepmc   +1 more source